WO2012050892A3 - Methods for stimulating, increasing or enhancing killing of a cell that expresses luteinizing hormone releasing hormone (lhrh) receptors - Google Patents

Methods for stimulating, increasing or enhancing killing of a cell that expresses luteinizing hormone releasing hormone (lhrh) receptors Download PDF

Info

Publication number
WO2012050892A3
WO2012050892A3 PCT/US2011/053684 US2011053684W WO2012050892A3 WO 2012050892 A3 WO2012050892 A3 WO 2012050892A3 US 2011053684 W US2011053684 W US 2011053684W WO 2012050892 A3 WO2012050892 A3 WO 2012050892A3
Authority
WO
WIPO (PCT)
Prior art keywords
lhrh
stimulating
increasing
methods
expresses
Prior art date
Application number
PCT/US2011/053684
Other languages
French (fr)
Other versions
WO2012050892A2 (en
Inventor
Hector Alila
Rajasree Solipuram
Sita Aggarwal
William Hansel
Original Assignee
Esperance Pharmaceuticals, Inc.
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esperance Pharmaceuticals, Inc., Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College filed Critical Esperance Pharmaceuticals, Inc.
Publication of WO2012050892A2 publication Critical patent/WO2012050892A2/en
Publication of WO2012050892A3 publication Critical patent/WO2012050892A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The disclosure relates to compositions and methods for stimulating, increasing, or enhancing luteinizing hormone-releasing hormone (LHRH) receptor (LHRH-R) expression on cells with a first agent, to target cells for arrest, inhibition, reduction or decrease of cell growth, survival, or proliferation, or increased, stimulated, induced or enhanced cell killing, lysis or apoptosis with a second agent that binds to LHRH-R.
PCT/US2011/053684 2010-09-29 2011-09-28 Methods for stimulating, increasing or enhancing killing of a cell that expresses luteinizing hormone releasing hormone (lhrh) receptors WO2012050892A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38790410P 2010-09-29 2010-09-29
US61/387,904 2010-09-29

Publications (2)

Publication Number Publication Date
WO2012050892A2 WO2012050892A2 (en) 2012-04-19
WO2012050892A3 true WO2012050892A3 (en) 2014-04-03

Family

ID=45938868

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/053684 WO2012050892A2 (en) 2010-09-29 2011-09-28 Methods for stimulating, increasing or enhancing killing of a cell that expresses luteinizing hormone releasing hormone (lhrh) receptors

Country Status (1)

Country Link
WO (1) WO2012050892A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2889475A1 (en) 2012-10-30 2014-05-08 Esperance Pharmaceuticals, Inc. Antibody/drug conjugates and methods of use
CA2910311A1 (en) * 2012-11-15 2014-05-22 Esperance Pharmaceuticals, Inc. Follicle-stimulating hormone (fsh)/lytic domain fusion constructs and methods of making and using same
CN107106638A (en) * 2014-10-14 2017-08-29 激流生物科学有限公司 Peptide with anti-inflammatory property
US10130717B2 (en) 2015-12-04 2018-11-20 Eastern Kentucky University LHRH-platinum conjugates for treating reproductive cancers
US10413584B1 (en) 2018-08-29 2019-09-17 Riptide Bioscience, Inc. Peptides having immunomodulatory properties
US10548944B1 (en) 2018-10-19 2020-02-04 Riptide Bioscience, Inc. Antimicrobial peptides and methods of using the same
EP4051693A4 (en) * 2019-10-31 2023-11-15 Worcester Polytechnic Institute Lhrh-prodigiosin conjugates and methods of use
EP4051309A4 (en) * 2019-10-31 2023-11-08 Worcester Polytechnic Institute Lhrh-paclitaxel conjugates and methods of use
CN117003898B (en) * 2023-09-27 2023-12-29 贝格探索(成都)科技有限公司 LHRH4-CRM197-LF multimeric recombinant protein and preparation method and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060281685A1 (en) * 1999-03-17 2006-12-14 Michael Bernd Methods of treatment using novel lhrh antagonists having improved solubility properties
US20080027003A1 (en) * 2004-05-27 2008-01-31 Curepeptide Ltd. Peptides Useful for Treating Gnrh Associated Diseases
US20090087494A1 (en) * 2006-09-12 2009-04-02 Board Of Regents Of The University Of Nebraska Methods and Compositions for Targeted Delivery of Therapeutic Agents
US20090269341A1 (en) * 2008-01-24 2009-10-29 Esperance Pharmaceuticals Lytic domain fusion constructs and methods of making and using same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060281685A1 (en) * 1999-03-17 2006-12-14 Michael Bernd Methods of treatment using novel lhrh antagonists having improved solubility properties
US20080027003A1 (en) * 2004-05-27 2008-01-31 Curepeptide Ltd. Peptides Useful for Treating Gnrh Associated Diseases
US20090087494A1 (en) * 2006-09-12 2009-04-02 Board Of Regents Of The University Of Nebraska Methods and Compositions for Targeted Delivery of Therapeutic Agents
US20090269341A1 (en) * 2008-01-24 2009-10-29 Esperance Pharmaceuticals Lytic domain fusion constructs and methods of making and using same

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CLARK: "Antibody humanization: a case of the ''Emperor's new clothes?''", IMMUNOL TODAY., vol. 21, no. 8, 2000, pages 397 - 402, XP004215168, DOI: doi:10.1016/S0167-5699(00)01680-7 *
DHARAP ET AL.: "Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide.", PROC NATL ACAD SCI U S A., vol. 102, no. 36, 2005, pages 12962 - 7 *
HERMANN ET AL.: "No supra-additive effects of goserelin and radiotherapy on clonogenic survival of prostate carcinoma cells in vitro.", RADIAT ONCOL., vol. 2, no. 31, 2007, pages 1 - 10 *
KELLER ET AL.: "Receptors for Luteinizing Hormone Releasing Hormone Expressed on Human Renal Cell Carcinomas Can Be Used for Targeted Chemotherapy with Cytotoxic Luteinizing Hormone Releasing Hormone Analogues.", CLIN CANCER RES., vol. 11, no. 15, 2005, pages 5549 - 57, XP002390611, DOI: doi:10.1158/1078-0432.CCR-04-2464 *
KHAN ET AL.: "Cell proliferation effect of GnRH agonist on pathological lesions of women with endometriosis, adenomyosis and uterine myoma.", HUM REPROD., vol. 25, no. 11, 2010, pages 2878 - 90 *
MENG ET AL.: "Adhesion between peptides/antibodies and breast cancer cells.", J. APPL. PHYS., vol. 107, 2010, pages 114301. *

Also Published As

Publication number Publication date
WO2012050892A2 (en) 2012-04-19

Similar Documents

Publication Publication Date Title
WO2012050892A3 (en) Methods for stimulating, increasing or enhancing killing of a cell that expresses luteinizing hormone releasing hormone (lhrh) receptors
MX2013015168A (en) Glucagon/glp-1 receptor co-agonists.
MX2013015176A (en) Glucagon/glp-1 receptor co-agonists.
MX2021002406A (en) Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor.
CL2013003547A1 (en) Peptide derived from oxintomodulin; polynucleotide that encodes it; pharmaceutical composition that includes it; use of the peptide to treat obesity.
NZ712693A (en) Compositions and methods for immunotherapy
AR082340A1 (en) METHODS AND COMPOSITIONS FOR LIVER CANCER THERAPY
MX2015007751A (en) Anti-gdf15 antibodies.
NZ612297A (en) Glucagon analogs exhibiting gip receptor activity
MX2015016100A (en) Cryopyrin inhibitors for preventing and treating inflammation.
MX2015003643A (en) Method of treating cancer.
WO2012122535A3 (en) Stable formulations for parenteral injection of peptide drugs
ZA201405405B (en) Humanized anti-epiregulin antibody,and cancer therapeutic agent comprising said antibody as active ingredient
WO2011143152A3 (en) Acth for treatment of amyotrophic lateral sclerosis
WO2012078757A3 (en) Combination for breast cancer therapy with hsp90 inhibitory compounds
MY160556A (en) Neuregulin antagonists and use thereof in treating cancer
MX2014004074A (en) Methods of treating liver conditions using notch2 antagonists.
CA2908957C (en) Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX2013002162A (en) Methods of treating alcohol intoxication, alcohol use disorders and alcohol abuse which comprise the administration of dihydromyricetin.
MX2012013478A (en) Composition for preventing hair-loss or stimulating hair growth.
IL216847A0 (en) High-intensity active composition for pyrotechnic infra-red decoys
MX2019014301A (en) Means and methods for counteracting myeloproliferative or lymphoproliferative disorders.
IL216848A (en) Pyrotechnic active decoy composition for infra-red decoys
MX358211B (en) New differential-release pharmaceutical composition containing three active principles.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11833046

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 11833046

Country of ref document: EP

Kind code of ref document: A2